Clinical implications of inhibition of the late sodium current: ranolazine
Department of Cardiology, University Hospital Jean Minjoz, Boulevard Fleming, 25000 Besançon, France
* Corresponding author. Tel: +33 381 668 539; fax: +33 381 668 582. E-mail address: jean-pierre.bassand{at}ufc-chu.univ-fcomte.fr
Ranolazine is a unique anti-ischaemic drug that does not significantly affect haemodynamic parameters such as heart rate and blood pressure. Ranolazine has been shown in clinical trials to significantly prolong exercise duration and time to angina, as monotherapy or when administered with conventional anti-anginal therapy. It also reduces angina attacks and consumption of nitroglycerin and is well tolerated at therapeutic doses.
Key Words: Chronic stable angina Ranolazine Anti-ischemic agents Exercise stress testing